Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunnar Brobert

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
BMJ Open|September 23, 2019
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UKLuis Alberto García Rodríguez, Mar Martín-Pérez, Pareen Vora, et al.
Plos One|March 7, 2024
Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countriesAna Ruigómez, Tania Schink, Annemarie Voss, et al.
Expert Opinion on Drug Safety|February 16, 2023
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countriesLuis Alberto García Rodríguez, Ana Ruigómez, Tania Schink, et al.
BMC Nephrology|August 1, 2023
Incidence of hospital-acquired acute kidney injury and trajectories of glomerular filtration rate in older adultsNatalie Ebert, Alice Schneider, Doerte Huscher, et al.
European Heart Journal|January 26, 2018
Big data from electronic health records for early and late translational cardiovascular research: challenges and potentialHarry Hemingway, Folkert W Asselbergs, John Danesh, et al.
Thrombosis and Haemostasis|February 1, 2024
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK StudyAlexander T Cohen, Christopher Wallenhorst, Marcella Rivera, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 16, 2023
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US ProgramKimberly Snow Caroti, Alok A Khorana, Cecilia Becattini, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|July 12, 2023
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of BleedingKimberly Snow Caroti, Cecilia Becattini, Marc Carrier, et al.
Expert Opinion on Drug Safety|July 24, 2020
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practiceLuis Alberto García-Rodríguez, Mari-Ann Wallander, Leif Friberg, et al.
JACC. Cardiooncology|May 5, 2023
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous ThromboembolismCraig I Coleman, Kimberly Snow Caroti, Khaled Abdelgawwad, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
BMJ Open|September 23, 2019
Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UKLuis Alberto García Rodríguez, Mar Martín-Pérez, Pareen Vora, et al.
Plos One|March 7, 2024
Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countriesAna Ruigómez, Tania Schink, Annemarie Voss, et al.
Expert Opinion on Drug Safety|February 16, 2023
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countriesLuis Alberto García Rodríguez, Ana Ruigómez, Tania Schink, et al.
BMC Nephrology|August 1, 2023
Incidence of hospital-acquired acute kidney injury and trajectories of glomerular filtration rate in older adultsNatalie Ebert, Alice Schneider, Doerte Huscher, et al.
European Heart Journal|January 26, 2018
Big data from electronic health records for early and late translational cardiovascular research: challenges and potentialHarry Hemingway, Folkert W Asselbergs, John Danesh, et al.
Thrombosis and Haemostasis|February 1, 2024
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK StudyAlexander T Cohen, Christopher Wallenhorst, Marcella Rivera, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 16, 2023
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US ProgramKimberly Snow Caroti, Alok A Khorana, Cecilia Becattini, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|July 12, 2023
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of BleedingKimberly Snow Caroti, Cecilia Becattini, Marc Carrier, et al.
Expert Opinion on Drug Safety|July 24, 2020
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practiceLuis Alberto García-Rodríguez, Mari-Ann Wallander, Leif Friberg, et al.
JACC. Cardiooncology|May 5, 2023
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous ThromboembolismCraig I Coleman, Kimberly Snow Caroti, Khaled Abdelgawwad, et al.
Pageof 4